Pharmacological Characterization of the Nociceptin/Orphanin FQ Receptor Antagonist SB-612111 [(–)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5 H-benzocyclohepten-5-ol]: In Vitro StudiesBarbara Spagnolo, Girolamo Calò, Giacomo Carrà et al.|Journal of Pharmacology and Experimental Therapeutics|2007Cited by 97
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonistRaffaella Vergura, Girolamo Calò, Gianfranco Balboni et al.|Peptides|2007Cited by 86
Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone‐inducible mammalian expression systemJohn McDonald, David G. Lambert, Tim A. Barnes et al.|British Journal of Pharmacology|2003Cited by 74
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with Cα,α-dialkylated amino acidsMarika Arduin, Severo Salvadori, Girolamo Calò et al.|Bioorganic & Medicinal Chemistry|2007Cited by 59
UFP-101, a high affinity antagonist for the nociceptin/orphanin FQ receptor: radioligand and GTPγ35S binding studiesJohn McDonald, David G. Lambert, Girolamo Calò et al.|Naunyn-Schmiedeberg s Archives of Pharmacology|2003Cited by 45